Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial
| Autor: | Tadej, Battelino, Richard M, Bergenstal, Angel, Rodríguez, Laura, Fernández Landó, Ross, Bray, Zhentao, Tong, Katelyn, Brown |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
Adult
Blood Glucose Glycated Hemoglobin Blood Glucose Self-Monitoring Endocrinology Diabetes and Metabolism Gastric Inhibitory Polypeptide Glycemic Control Metformin Insulin Long-Acting Treatment Outcome Endocrinology Diabetes Mellitus Type 2 Internal Medicine Humans Hypoglycemic Agents Sodium-Glucose Transporter 2 Inhibitors |
| Zdroj: | The Lancet Diabetes & Endocrinology. 10:407-417 |
| ISSN: | 2213-8587 |
| DOI: | 10.1016/s2213-8587(22)00077-8 |
| Popis: | Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist under development for the treatment of type 2 diabetes. In this study, we used continuous glucose monitoring (CGM) to compare the 24 h glucose profile for participants given tirzepatide compared with those given insulin degludec.This substudy of the open-label, parallel-group, phase 3 SURPASS-3 trial, was done at 45 sites across six countries (Hungary, Poland, Romania, Spain, Ukraine, and the USA). Eligible participants in the main study were adults with type 2 diabetes, a baseline HbAFrom April 1 to Nov 27, 2019, 313 participants were screened for eligibility, 243 of whom were enrolled in CGM substudy (tirzepatide 5 mg, n=64; tirzepatide 10 mg, n=51; tirzepatide 15 mg, n=73; and insulin degludec, n=55). Patients given once-weekly tirzepatide (pooled 10 mg and 15 mg groups) had a greater proportion of time in tight target range compared with patients given insulin degludec (estimated treatment difference 25% [95% CI 16-33]; p0·0001). Participants assigned to tirzepatide spent significantly more time in tight target range at 52 weeks compared with those assigned to insulin degludec (5 mg 12% [1-22], p=0·031; 10 mg 24% [13-35], p0·0001; and 15 mg 25% [14-35], p0·0001). Participants assigned to tirzepatide 10 mg and 15 mg, but not to tirzepatide 5 mg, spent significantly more time in tight target range at 24 weeks compared with insulin degludec (10 mg 19% [8-30], p=0·0008; 15 mg 21% [11-31], p0·0001).Once-weekly treatment with tirzepatide showed superior glycaemic control measured using CGM compared with insulin degludec in participants with type 2 diabetes on metformin, with or without a SGLT2 inhibitor. These new data provide additional evidence to the effect of tirzepatide and potential for achieving glycaemic targets without increase of hypoglycaemic risk compared with a basal insulin.Eli Lilly and Company. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|